AXIM® Biotechnologies to Present at 28th Annual International Cannabinoid Research Society Symposium in The Netherlands
NEW YORK, June 28, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that the company will be attending as a sponsor. at the 28th Annual International Cannabinoid Research Society (ICRS) Symposium taking place in Leiden, The Netherlands from June 30 – July 5, 2018. AXIM’s Advisory Board Member and Chairman of Pharmacology at the University of Wageningen, Professor Dr. Renger Witkamp, will present the results from its phase IIA clinical trial for the treatment of irritable bowel syndrome (IBS) with the company’s CanChew® Plus 50 mg cannabidiol (CBD) functional, controlled-release chewing gum.
“We are always excited for opportunities like this prestigious, scientific symposium to showcase and educate audiences on AXIM’s ongoing research with cannabinoid molecules and their potential for the treatment of various indications, in this case our IBS clinical trial results,” said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM® Biotech. “We look forward to sharing our accomplishments within the cannabinoid research community and learning about other innovative research being done in the industry.”
The International Cannabinoid Research Society (ICRS) is a non-political organization dedicated to scientific research regarding cannabinoids, ranging from biochemical, chemical, and physiological studies of the endogenous cannabinoid system to studies of the abuse potential of recreational cannabis. In addition to acting as a source for impartial information on cannabis and cannabinoids, the main role of the ICRS is to provide an open forum for researchers to meet and discuss their clinical studies.
IBS is the most common gastrointestinal disorder with a prevalence worldwide ranging from 9-23% of the general population. Complaints include abdominal discomfort or pain and altered bowel habits. Although the condition is not life-threatening, it strongly impairs quality of life and up to now there is no cure for IBS currently on the market.
AXIM® Biotech is a gold sponsor of the 28th annual ICRS Symposium. AXIM representatives will be available onsite to discuss the company’s current research and product pipeline, as well as potential business and investment prospects at the conference.
For more information about the ICRS and the upcoming 2018 Symposium, please visit http://icrs.co/.
About AXIM® Biotechnologies
AXIM® Biotechnologies, Inc. (AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew+®, a CBD-based controlled release chewing gum, CanChew+ 50®, containing 50 mg of CBD undergoing clinical trials in patients with IBS and MedChew Rx®, a combination CBD/THC gum that will undergo clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. AXIM has several products developed or in developmental stage for treatment and/ or prevention of multiple conditions and symptoms. We prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, please visit AXIMBiotech.com.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.
AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).
Public Relations Contact:
Chief Executive Officer
Corporate Contact Info:
North American Address:
45 Rockefeller Plaza, 20th Fl.
New York, NY 10111, USA
P. 844 294 6246
Industrieweg 40, Unit B4
3401 MA IJsselstein
Released June 28, 2018